ResMed Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M |
| Depreciation & Amortization | $201.3M | $198.5M | $176.9M | $165.2M | $159.6M | $156.8M | $154.9M | $150.8M |
| Depreciation | $103.0M | $112.0M | $89.0M | $84.7M | $81.0M | $78.4M | $65.6M | $65.9M |
| Amortization | $31.8M | $32.1M | $33.0M | $30.4M | $39.7M | $45.1M | $49.6M | $42.5M |
| Stock-Based Compensation | $104.3M | $91.7M | $80.2M | $71.1M | $65.3M | $63.9M | $57.6M | $52.1M |
| Net Cash from Operating Activities | $1.81B | $1.75B | $1.40B | $693.3M | $351.1M | $736.7M | $802.3M | $459.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $156.3M | $89.9M | $99.5M | $119.7M | $134.8M | $102.7M | $95.3M | $68.7M |
| Business Acquisitions | $350.7M | $139.2M | $133.5M | $1.01B | $42.8M | $39.1M | $27.9M | $951.4M |
| Net Cash from Investing Activities | $-545.2M | $-200.0M | $-269.8M | $-1.16B | $-229.9M | $-158.5M | $-179.9M | $-1.08B |
| Financing Activities | ||||||||
| Dividends Paid | $349.7M | $310.9M | $282.3M | $258.3M | $245.3M | $226.7M | $225.1M | $211.7M |
| Stock Repurchases | $700.0M | $300.0M | $150.0M | $0 | $0 | — | — | $22.8M |
| Net Cash from Financing Activities | $-1.01B | $-606.3M | $-1.12B | $422.9M | $-128.4M | $-764.6M | $-317.3M | $580.6M |
| Net Change in Cash | $259.8M | $971.1M | $10.5M | $-45.8M | $-21.6M | $-167.9M | $316.0M | $-41.6M |
| Free Cash Flow | $1.65B | $1.66B | $1.30B | $573.6M | $216.3M | $634.0M | $706.9M | $390.3M |